



Cell4Cure Secures Patent Approval in Japan

Solna, Stockholm Region, Sweden – March 9, 2026 – Swedish biotech company Cell4Cure AB, specializing in immune tolerance therapies via autologous tolerogenic dendritic cells (tolDCs), today announced the formal grant of a key patent in Japan. This achievement reinforces Cell4Cure's intellectual property position and extends the company's patent protection to include the Japanese market.

The patent is set to remain in force until December 2040. This approval covers Cell4Cure's proprietary method for generating tolerogenic dendritic cells, further protecting the company's technological advancements and its mission to develop immune tolerance therapies globally.

"The grant of this Japanese patent is an important step for Cell4Cure, reflecting our focus on innovation and international expansion," said Christina Herder, CEO of Cell4Cure. "This strengthens our foundation for future partnerships in Japan and provides further momentum as we await upcoming patent decisions in other jurisdictions."

For more information, please contact:

Christina Herder, CEO

Telephone: +46703747156

Email: christina.herder@cell4cure.com

About Cell4Cure

Founded in 2023, Cell4Cure AB is a Swedish biotech company pioneering immune tolerance therapies to address critical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejection. The company's proprietary platform is based on ex vivo-engineered dendritic cells (DCs) designed to induce antigen-specific immune tolerance while preserving essential immune function. Backed by \$30 million in research and development investments, Cell4Cure has achieved key milestones, including European Medicines Agency (EMA) approval for clinical trials and the establishment of robust GMP manufacturing processes.

Cell4Cure AB | Org nr: 559445-7979

Gustav III:s Boulevard 10, 16972 Solna, Sweden

Website: www.cell4cure.com

[Cell4Cure](#) | [LinkedIn](#)